TABLE 1.

Summary of the clinical characteristics of patients with LGV reported in this study

Patient age (yr)	Risk factors	HIV	No. of CD4 cells/mm3	Viral load (copies/ml)	Antiretroviral therapye	Clinical presentation	Other STI(s)	Treatment
43	MSM, lived in United States	+	298	NAc	d4T, 3TC, lopinavir-ritonavir	PRb bleeding, diarrhea; colonoscopy showed multiple ulcerative rectal lesions, probable Crohn's disease	Kaposi's sarcoma	Azithromycin, doxycycline
55	MSM, no travel	+	310	<50	Abacavir, 3TC, nevirapine	Tenesmus, rectal bleeding for 3 mo; high-resolution anoscopy showed extensive ulcer distal to dentate line	Anal warts, syphilis	Doxycycline
54	MSM, no travel, SOPa venues	+	571	<50	Abacavir, tenofovir, atazanavir-ritonavir	PR bleeding, sweats, lethargy for 10 days; colonoscopy showed ulcerated tumor, SCCd?	Syphilis	Doxycycline
45	MSM, no travel, SOP venues	+	442	130	Abacavir, 3TC, nevirapine	Anal ulceration, concurrent HSV2f infection	Tertiary-stage syphilis, gonorrhea, HSV2, HCVg	Azithromycin

^aSOP, sex on premises.

^bPR, per-rectal.

^cNA, not available.

^dSCC, squamous cell carcinoma.

^ed4T, stavudine; 3TC, lamivudine.

^fHSV2, herpes simplex virus type 2.

^gHCV, hepatitis C virus.